General discussion, page-15738

@general86 Everyone has low expectations ATM, good investors buy during periods of low expectations.

@tossydog - The following Catalyst/s - IMO will lead to much higher expectations for Incannex.

The Psychedelics Industry is going to get some real exposure in the coming months

MAPS PBC is going to make their NDA submission to the FDA for their MDMA Treatment for PTSD in Q3 this year.



Follow up Trials have re-confirmed the treatment with patients six months out

https://mapsbcorp.com/category/press-releases/

>> It has been reported that MAPS PBC will receive FDA Approval in Q1 - 2024 if not earlier. FDA approval will be an inflection point for the Psychedelic Industry IMO and there is commentary that approval for just one indication in the Psychedelics space will be worth $Billions

>> Dr Rick Doblin (the founder) is on a mission to make this treatment readily available and has postulated that floating the MAP PBC might be an avenue worth considering to achieve that goal. (with the possibility of up to 1.9m Veterans eligible for sponsored treatment)

.............................................
Regarding IHL-42X

IHL investors couldn't wish for a better "Perfect Storm"

Q3-Q4
IHL-42X will have USA Trials underway and release regular DATA updates to the market.
PSI-GAD will be close to completing the Phase 2 Trial (if not already completed) around the time MAPS PBC Files their NEW DRUG Application with the FDA, while Incannex is due to submit a new IND for PSI-GAD around the same period (maybe)

IHL will be IMO entering a period of "High Expectation" in the coming months due to pending PSI Industry Developments and will likely get some free kicks from IHL-42X trial updates too!

In the shorter term - we can expect the milestones, which I have posted countless times

GLAH